Pharmaceutical major Wockhardt has announced a decisive pivot in its global strategy by exiting the US generics market to concentrate on its foundational strength in antibiotics. This move reflects the company’s intent to redeploy resources toward high-value specialty and novel antibiotic segments, where it holds substantial intellectual property and manufacturing advantages.